Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in...

Ogkologos - 10 Μαΐου, 2024

Alectinib Approved as an Adjuvant Treatment for Lung Cancer

Ogkologos - 8 Μαΐου, 2024

ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany

Ogkologos - 8 Μαΐου, 2024

FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

Ogkologos - 8 Μαΐου, 2024

NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in...

Ogkologos - 8 Μαΐου, 2024

Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and...

Ogkologos - 7 Μαΐου, 2024

EMA Recommends Extension of Indications for Amivantamab

Ogkologos - 6 Μαΐου, 2024

FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer

Ogkologos - 3 Μαΐου, 2024

Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H...

Ogkologos - 3 Μαΐου, 2024

FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or...

Ogkologos - 2 Μαΐου, 2024

1...838485...440 Σελίδα 84 από 440

MOST POPULAR

Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in...

3 Μαρτίου, 2021

Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with...

21 Σεπτεμβρίου, 2020

¿Puede protegerlo un “bronceado base” de las quemaduras solares y del...

31 Αυγούστου, 2023

FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma

6 Ιουνίου, 2025

Φόρτωση περισσοτέρων

Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in...

Alectinib Approved as an Adjuvant Treatment for Lung Cancer

ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany

FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in...

Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and...

EMA Recommends Extension of Indications for Amivantamab

FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer

Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H...

FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or...

MOST POPULAR

Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in...

Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with...

¿Puede protegerlo un “bronceado base” de las quemaduras solares y del...

FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma

HOT NEWS

FDA Approval Likely to Change Initial Treatment for Some People with...

Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,...

EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib

Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer?

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ